DSP-2230
DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. As of June 2014, it is in phase I/ phase II clinical trials. See also * List of investigational analgesics This is a list of investigational analgesics, or analgesics that are currently under development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in pare ... References External links * Amines Analgesics Cyclobutyl compounds Ethers Fluoroarenes Imidazopyridines Sodium channel blockers {{Analgesic-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]